

















































































































































































































































































































































































































































































































































































































































































































































































































































point of view, it does not require a nebulizer and can be
performed outside the laboratory setting using a simple hand
held inhaler device, the mannitol being contained in gelatin
capsules. In vitro, the human lung mast cell has been shown to
release histamine in response to a hyperosmolar stimulus; at
the same osmolarity, mannitol was found to be more potent
than sodium chloride [24]. Recently, it has also been shown
that hyperosmolar stimulation with mannitol resulted in
leukotriene C4 release from human peripheral blood eosino-
phils in vitro [25]. The presence of mast cell activation is
further suggested by the observation that mannitol-induced
bronchoconstriction is associated with increased urinary
levels of the prostaglandin D2 (PGD2) metabolite and mast
cell marker 9a,11b-PGF2, and of leukotriene E4 (LTE4) [26].
Another interesting supportive finding was the quite close
correlation, in asthmatics, between the BHR to mannitol and
to adenosine 50-monophosphate (AMP), a stimulus which is
thought to act largely through mast cell-dependent mechan-
isms [27]. Pre-treatment with specific mediator antagonists
suggests a different role for histamine and leukotrienes; it has
been shown that pre-treatment with the H1 antagonist
fexofenadine (two 180mg doses taken over 14 h) decreased
the airway sensitivity in asthmatic patients, while the cysLT1
antagonist montelukast (three 10mg doses taken over 36 h)
shortened the recovery time [28]. Similar results were
described in a second study in asthmatics, in which the
effects of 10mg montelukast, alone or in combination with
5mg of the H1 antagonist desloratidin, were studied on
mannitol and AMP challenge; interestingly, the effects
observed on both challenges appeared again quite similar
[29]. As is the case with all indirect challenges, pre-treatment
with 8mg of inhaled nedocromil sodium was found to
significantly inhibit the responsiveness to inhaled mannitol in
asthmatic subjects [30]. Finally, a pilot study on 18 asthmatics
suggested that 6–9 weeks of inhaled corticosteroids (ICS)
(budesonide (BUD) 800–2400mg/day) reduces sensitivity and
reactivity to mannitol [31] (Table 3).
Receptors
In addition, the development of specific antagonists for
adenosine and TK receptors is currently opening new
research directions. These molecules will not only allow to
determine which receptors are involved in the adenosine and
TK-induced airflow limitation, but will ultimately permit to
conclude, by performing appropriate clinical trials, whether
or not adenosine and TKs are asthma mediators of clinical
relevance.
The adenosine receptor pharmacology in human airways is
being increasingly studied in vitro; adenosine exerts its effects
on human cells through interaction with specific adenosine
(P1) receptors, of which four subtypes (A1, A2A, A2B, and A3)
have been described [32]. Different animal models, among
which knock-out mice for specific adenosine receptors [32] or
mice, deficient for adenosine deaminase, a purine catabolic
enzyme that converts adenosine to inosine [33], have provided
insights into the physiology and pathophysiology of the
different adenosine receptors. However, there are important
interspecies differences and these results cannot be extra-
polated as such to the human situation. Although the relative
importance of the various adenosine receptor subtypes in
asthma remains to be further elucidated, it appears that
stimulation of adenosine A2B receptors on the surface of
human lung mast cells is the main trigger for adenosine-
induced airflow limitation [34, 35]; in addition, its relevance
has recently been further illustrated by the finding that
adenosine increases cytokine release by human bronchial
muscle cells in vitro via an A2B-mediated mechanism [36]. The
results of a rabbit study using an aerosolized antisense
oligodeoxynucleotide to reduce the number of A1 receptors
Table 1. Classification of bronchial challenge tests according to their main
mechanism
Direct stimuli Indirect stimuli
Pharmacological stimuli Pharmacological stimuli
Cholinergic agonists Adenosine (AMP)






Physical and physicochemical stimuli
Exercise
Isocapnic hyperventilation with (cold) dry air
Osmotic stimuli
Hypertonic aerosols (e.g. HS)
Hypotonic aerosols (e.g. UNDW)
Hypertonic mannitol dry powder
AMP, adenosine 50-monophosphate; SP, substance P; NKA, neurokinin A;















Fig. 1. Mechanisms via which direct and indirect stimuli induce airflow
limitation.
Indirect bronchial hyper-responsiveness 251






















































































in FEV1 for exercise and EVH to the average fall in FEV1 by
exercise and EVH. A p value ! 0.05 was considered statistically
significant for all analyses; all values are presented as mean" SD.
Results
Baseline lung function values and the fall in FEV1
in response to exercise and EVH for the 38 subjects
are given in Table 1. Values for pulmonary function
variables at baseline exceeded the normative pre-
dicted values for age, height, and gender, and were
in accord with resting values of elite athletes.5 No
differences in values expressed as percentage of
predicted were found between those who were
positive or negative (p# not significant [NS]). Based
on a ! 10% fall in FEV1 from baseline, there were
11 subjects positive to exercise (EX$) and 17 sub-
jects positive to EVH (EVH$).
Among the 11 EX$ subjects, the percentage fall
in FEV1 was 20.5" 7.3%; for those 27 subjects who
were negative to exercise (EX%), the fall was
4.5" 2.5% (p! 0.05). The 17 EVH$ subjects dem-
onstrated a percentage fall in FEV1 of 14.5 " 4.5%;
for the 21 subjects who were negative to EVH
(EVH%), the fall was 4.7" 3.2% (p! 0.05). Of the
17 EVH$ subjects, 9 subjects were EX$. Twenty-
eight subjects had concordant findings, that is, they
were positive to both or negative to both exercise and
EVH (odds ratio, 10.7; Table 2). The effectiveness of
the EVH test in identifying those EIB positive
during exercise is presented in Table 3.
Among the 11 EX$ subjects, 7 subjects had
greater falls in FEV1 on exercise compared with
EVH (23.1" 8.2% vs 11.7" 3.4%, p! 0.05); in 1
subject, the fall was the same. For the 17 EVH$
subjects, 11 subjects had greater falls in FEV1
compared with exercise (15.1" 5.3% vs 7.6" 6.0%,
p ! 0.05); in 1 subject, the fall was the same (Fig 1).
In all, there were 8 EVH$/EX% subjects and 2
EX$/EVH% subjects. One of these EX$/EVH%
subjects performed exercise for 2 min longer than
EVH. Figure 2 plots the difference between exercise
and EVH postchallenge falls in FEV1 against an
estimate of the true value determined as the mean of
the two challenges (0.14" 8.35%). The difference
between challenges was normally distributed around
the mean of exercise and EVH challenges.
Twenty-two subjects performed both exercise and
EVH for 6 min, and the percentage fall to exercise
was 11.3" 10.0% and to EVH was 12.0" 5.5%
(p # NS). Of these 22, 9 subjects were EX$ and 15
subjects were EVH$ (Fig 3). In this group, only one
subject was EX$ (14.5% fall) and EVH% (7.77%
fall).
Ventilation was measured during EVH for all
Figure 1. The maximum fall in FEV1, expressed as a percentage
of the baselin value, documented in the 15 min after 6 min of
EVH of dry air (containing 5% carbon dioxide) at a target
ventilation rate equivalent to 30 times FEV1, in relation to the fall
in FEV1 after exercising for 6 to 8 min at 2" 5.6°C, with relative
humidity of 45" 21.3%, 717" 21.3 mm Hg. The subjects were
eli e athletes wh performed exercise by cross-country skiing, ice
skating, or running. The lines represent the 10% cutoff point
commonly used to define AHR to exercise and EVH. Note that
two subjects were EVH% but EX$ and eight subjects were
EVH$ and EX%.
Table 2—Results of the Two Challenges*
EX$, No. EX%, No. Total, No.
EVH$ 9 8 17
EVH% 2 19 21
Total 11 27 38
*A positive response was defined as a ! 10% fall in FEV1 from
baseline measurements.
Table 3—Effectiveness of EVH as a Test for EIB as




Positive predictive value‡ 53
Negative predictive value§ 90





!(True-positive) $ (true-negative)/all subjects.
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knowledge of patients! AHR to mannitol has been shown
to be useful in guiding the reduction of inhaled cortico-
steroid doses (30).
In conclusion, inhaled mannitol is a useful, practical
means of assessing AHR and correlates closely to the
airway response following inhaled AMP. Further studies
are required to determine whether AHR to inhaled dry
powder mannitol in the outpatient clinic, in conjunction
with conventional markers of asthma control, leads to
clinically relevant reductions in asthma exacerbations,
than use of the latter alone.
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Figure 1. Correlations between (A) AMP PC20 vs mannitol




Figure 2. Altman Bland plots showing the repeatability between
(A) AMP and (B) mannitol on screening and placebo days. The
solid line indicates the point of no difference between days and
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corticosteroids and were also hyperresponsive to AMP. One of 
these skiers was also hyperresponsive to mannitol. 
 In the methacholine-negative skiers, doctor-diagnosed 
asthma was reported by six subjects. Of these, three reported 
the use of inhaled corticosteroids, one was hyperresponsive to 
mannitol and another was hyperresponsive to AMP. 
 The distribution of AHR to methacholine, AMP, mannitol, 
EVH and fi eld exercise by asthma-like symptomatology for 33 
skiers is presented in  fi gure 4 . One skier with AHR to EVH 
and fi ve skiers with AHR to exercise did not previously report 
asthma-like symptoms. One skier with AHR to both tests 
reported asthma-like symptoms. 
 Exhaled nitric oxide concentration 
 F E NO was measured in 44 subjects before challenge with 
mannitol, AMP and methacholine. The median (IQR) F E NO 
on mannitol, methacholine and AMP challenge days was 
4.1 ppb (3.5–5.4), 6.7 ppb (4.9–8.4) and 5.2 ppb (3.9–7.6) 
(p<0.001), respectively. F E NO was signifi cantly higher on the 
methacholine (p<0.001) and AMP (p<0.01) challenge days 
than on the mannitol challenge day. 
 F E NO before methacholine challenge was not signifi cantly dif-
ferent in skiers with and without hyperresponsiveness to meth-
acholine (median (IQR) 7.3 (4.3–8.6) vs 6.5 (5.2–8.2) p=0.89). 
There was no correlation between F E NO and the response–dose 
ratio for methacholine (N=58, r s =−0.074, p=0.848). 
 Allergic sensitisation 
 Allergic sensitisation was present in 12 of 16 subjects with 
self-reported allergy, fi ve of 33 subjects without self-reported 
allergy and in three of nine subjects who were uncertain about 
their allergy status. 
 DISCUSSION 
 The airways of elite skiers clearly react in a heterogeneous 
manner in the training season in the autumn, being more 
responsive to methacholine than to AMP and mannitol. 
Methacholine hyperresponsiveness, defi ned as a PD 20 FEV 1 of 
1800 μg or less, was present in 40% (23) of skiers. By contrast, 
provocation with AMP and mannitol identifi ed AHR only in 
fi ve and three subjects, respectively. Additional provocation 
with EVH and fi eld exercise tests at 1 month into the competi-
tive season detected hyperresponsiveness in eight skiers. 
 A number of studies report a high prevalence of AHR in 
winter athletes. 4  7  18  19 This study confi rms that high preva-
lence and extends the fi nding to report that the AHR to metha-
choline was more prevalent in those not reporting asthma-like 
symptoms. Furthermore, asthmatic airway infl ammation was 
not a prerequisite for AHR to methacholine. The values for 
F E NO were normal and consistent with the mild AHR with 
a PD 20 of 486 µg (342–929). In the skiers with methacholine 
hyperresponsiveness, 10 (17%), eight steroid-naive skiers with 
a PD 20 FEV 1 of 400 μg or less and two skiers on inhaled cor-
ticosteroids would have satisfi ed the criteria for a therapeutic 
use exemption for β 2 agonists for the 2008 Olympic Games. 20 










 Figure 2  Interrelationship of airway hyperresponsiveness to 
methacholine, adenosine 5′-monophosphate (AMP), mannitol and 
hyperpnoea (eucapnic voluntary hyperventilation a d fi eld exercise 


























 Figure 3  Prevalence of airway hyperresponsiveness to 
methacholine, adenosine 5′-monophosphate (AMP) and mannitol in 58 
skiers related to self-reported asthma symptomatology (wheeze and 
abnormal breathlessness or chest tightness, either on exertion, at rest 






























Any kind of AHR
 Figure 4  Prevalence of airway hyperresponsiveness (AHR) to 
methacholine, adenosine 5′-monophosphate (AMP), mannitol 
eucapnic voluntary hyperventilation (EVH) and fi eld exercise related to 
asthma symptomatology in 33 skiers. 
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RESPIRATORY HEAT EXCHANGE AND ASTHMA 
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FIG. 4. Relationship between respiratory heat exchange (RHE) dur- 
ing exercise and postexertional percentage change in l-s forced expi- 
ratory volume (%AFEVI). These data were computed from Refs. 28 and 
29. 
constant. With dry air, to bring about an RHE of zero 
and thus abolish the postexercise response, a Ti of 107OC 
would be required to provide enough heat in the inspired 
air to precisely replace mucosal losses from vaporization. 
At the other extreme of this graph, the 0 and 100% rh 







FIG. 3. Effect of exercise on pulmonary me- 
chanics in subjects breathing air at 50°C that is dry 
(solid circles) vs. that containing 15.8 mgHzO/l 
(open circles). Data points are mean values, and 
brackets are 1 SE. Letters B and R below each 
graph represent base-line data and response ob- 
served postexercise, respectively. First two P val- 
ues below each were derived from base line-re- 
sponse comparisons and third from a comparison 
of dry and wet data. SGaw, specific conductance; 
FE&, l-s forced expiratory volume; RV, residual 
volume. 
hold very little water. For example, the difference be- 
tween the water content in fully saturated and dry air at 
-1OOC is only 2.4 mg (31). Consequently, this factor does 
not have much of an influence upon the postexercise 
response seen at these temperatures. 
Comparisons of observed and predicted responses. 
Superimposition of the observed dry gas responses on 
the theoretical results demonstrates that the predicted 
and experimentally determined data are virtually iden- 
tical from subfreezing through body temperature ranges 
(Fig. 6). Comparison of the RHE-AFEV1 relationship 
computed for this temperature range in dry gas experi- 
ments with that from the previous studies shown in Fig. 
4 demonstrates that they, too, are identical (Fig. 7). From 
50°C on, however, the actual responses in Fig. 6 were 
somewhat greater than those expected. As indicated 
above, we believe that the explanation for the latter 
phenomenon is probably related to a loss of heat from 
the inspired air to the mucosa of the mouth and pharynx 
before reaching the intrathoracic airways. There are two 
interrelated factors that would influence the magnitude 
and rate of this transfer. The first is the geometries of 
the conduits that are involved and the second is the 
duration of breathing the gas. 
With respect to geometric considerations one can think 
of the supra- and infraglottic airways as two heat ex- 
changers in series. In the supraglottic airways airflow is 
quite turbulent, the surface area is large relative to that 
of the trachea and major bronchi, and the greatest ther- 
mal gradients between air and mucosa exist. All of these 
factors would favor contact between the gas and mucosa 
and would facilitate loss of heat from the air (12, 20). 
With the passage of time, however, the initial thermal 
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Cooling of the airways and surrounding microvasculature  
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FIG. 5. Maximal and minimal postexercise responses possible at response for dry gas for same exercise task. Equations I and 2 are 
extremes of humidity over temperature ranges from -11 to +llO”C. formulations for respiratory heat exchange (RHE) and regression equa- 
Solid Lines and cirdes represent the mean responses t_ 1 SE observed tion used to calculate the percentage change in l-s forced expiratory 
in subjects breathing fully saturated air at various temperatures in volume (%AFEV,) from RHE. Ti, inspired air temperature. 
previous studies from this laboratory (Z&29). Broken curve is predicted 
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FIG. 6. Actual data for maximal and minimal postexercise responses work. Data points are mean values, and brackets indicate 1 SE. Curve 
at extremes of humidity. SoLid circZes are data from previous studies with open circZes and broken Line represents predicted dry gas response. 
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Fig. 8. Comparison ofthe cumulative water loss after 4 min ofexercise at VE - 60 L" min-  ~ (Vt -- 2600 mi, 
f = 23' min - i Ti = 26.7 °C, Wi = 8.8 mg'  L-  ~), with the available periciliary fluid throughout the respira- 
tory tract. 
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Fig. 9. Comparison ofthe cumulative water loss after 4 min ofexercise at VE = 60 L. min-  ~ (Vt = 2600 ml, 









































In the short term, breaches in the airway epithelial barrier could, among other
events, transiently facilitate the passage of inhaled substances (ie, viruses, bacteria,
allergens, or airborne pollutants or irritants) across the airway epithelium and increase
the interaction of those substances with resident immune and inflammatory cells,
trigger an inflammatory response with consequent infiltration of mast cells51 and sec-
ondary influx of neutrophils,49 cause the loss of the bronchoprotective agent prosta-
glandin E2,
46,52 and impede mucociliary clearance.53 Either alone or in combination,
these factors could initiate acute airway narrowing following exercise.
DOES MECHANICAL STRESS CONTRIBUTE TO AIRWAY INJURY?
Although dehydration stress is regarded as the most important precursor of airway
epithelial injury during exercise, the role of mechanical stress cannot be excluded.
During respiration, the airways are subjected to complex physical forces. Movement
of air across the surface of the airway imparts a shear stress on the surface epithelium.
Mathematical modeling has shown that at a peak flow rate of 1 L/s (representing
normal expiratory flow), wall shear stress in the major airways reaches up to
0.9 Pa.54 At 8 L/s (representing cough), the maximum value for wall shear stress rises
to 19 Pa.54 Cough, through wall shear stresses, is thought to be a contributing factor to
A B
Fig. 2. Epithelial cells and ion transport under basal conditions (A) and hyperosmotic stress
during dry air hyperpnoea (B). Under basal conditions, Na1 ions are absorbed via an apical
sodium channel, and Cl- ions move paracellularly. Under basal conditions, water moves into
the epithelial cells and submucosa due to the osmotic gradient created by the movement of
these ions. During hyperpnoea, evaporative water loss reduces the pericilary fluid layer and
increases the ion concentration, which creates an osmotic stimulus for water to move out of
the epithelial cells. As a result, the epithelial cells shrink, creating an osmotic stimulus for
water to move from the submucosa. Hyperosmolarity of the epithelial cells and the submu-
cosa is a possible stimulus for the release of nitric oxide (NO) and prostaglandins (PGs). These
substances may contribute to the increase in the blood flow documented in people
breathing dry air. (From Anderson SD, Daviskas E. Airway drying and exercise-induced
asthma. In: McFadden ER, editor. Exercise-induced asthma—lung biology in health and
disease. N w York: Ma cel Dekker; 1999. p. 91; with permission.)
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EIB AND EOSINOPHILIC INFLAMMATION 881
methacholine solution from a Devilbiss 646 nebulizer
(Devilbiss Co., Somerset, PA, USA) operated with com-
pressed air at 5 L·min-1. They inhaled saline or methacho-
line solution for 2 min by tidal breathing while wearing a
noseclip. Spirometry was performed with a Chestac-25F
system immediately after inhalation and FEV1 was meas-
ured. After a fall in FEV1 of <10% following saline inha-
lation, the methacholine challenge was started. Subjects
successively inhaled methacholine solutions of cumula-
tive concentrations and the test was stopped when a fall in
FEV1 of Š20% below the baseline occurred. The meas-
ured values were plotted on a semilogarithmic graph and
the provocative concentration of methacholine causing a
20% fall in the FEV1 (PC20) was calculated in noncumu-
lative units by linear interpolation between the last two
points on the graph.
Statistical analysis
Data were analysed nonparametrically. Group data were
expressed as median with the range given in parentheses
because a normal distribution of these variables could not
be demonstrated. When multiple comparisons were made
between groups, significant intergroup variability was first
established using the Kruskal-Wallis test. The Mann-Whit-
ney U-test was then used for intergroup comparisons. The
significance of correlations was evaluated by determining
Spearman's rank correlation coefficients. A p-value <0.05
was considered significant.
Results
The 21 asthmatic subjects and nine normal control sub-
jects produced adequate sputum specimens. All subjects
tolerated the sputum induction procedure well. There was
no significant decrease in FEV1 after sputum induction in
any subject and no subject experienced shortness of breath
or chest tightness. There were no significant differences in
the temperature and humidity during the exercise test be-
tween EIB-positive and EIB-negative asthmatics. Figure 1
shows the percentages of eosinophils and the ECP concen-
trations in induced sputum. The percentage of eosinophils
was significantly higher in EIB-positive asthmatic sub-
jects (median (range), 23.5 (11.0–61.0)%) than in EIB-
negative asthmatic patients (6.0 (1.0–41.5)%) (p=0.006)
and normal control subjects (0.0 (0.0–1.4)%) (p=0.0002).
ECP concentrations were also significantly higher in EIB-
positive asthmatic patients (1,475 (74.8–17,701) ng·mL-1)
than in EIB-negative asthmatic patients (270.6 (10.8–7,700)













































Fig. 1.  –  Comparison of indices of eosinophilic inflammation in induced sputum between controls and asthmatic patients with or without exercise-
induced bronchoconstriction (EIB). Horizontal bars indicate the median values. a) The percentage of eosinophils was significantly higher in EIB-posi-
tive asthmatics than in EIB-negative asthmatic patients and normal control subjects. b) Eosinophil cationic protein (ECP) concentrations were also






































Fig. 2.  –  Correlation between indices of eosinophilic inflammation in
induced sputum and severity of exercise-induced bronchoconstriction
(EIB). a) There was a significant correlation between severity of EIB
and sputum eosinophil percentage (r=0.59, p=0.009). b) EIB severity
was also positively correlated with eosinophil cationic protein (ECP)
concentrations (r=0.47, p=0.037).
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Fig. 1.  –  Comparison of indices of eosinophilic inflammation in induced sputum between controls and asthmatic patients with or without exercise-
induced bronchoconstriction (EIB). Horizontal bars indicate the median values. a) The percentage of eosinophils was significantly higher in EIB-posi-
tive asthmatics than in EIB-negative asthmatic patients and normal control subjects. b) Eosinophil cationic protein (ECP) concentrations were also






































Fig. 2.  –  Correlation between indices of eosinophilic inflammation in
induced sputum and severity of exercise-induced bronchoconstriction
(EIB). a) There was a significant correlation between severity of EIB
and sputum eosinophil percentage (r=0.59, p=0.009). b) EIB severity


























































































MEDIATORS IN EXERCISE-INDUCED ASTHMA 543 
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Fig. 1. - Percentage falls in FEV 1 over 30 m in from pre-exercise baseline values following exercise challenge for each of the drug treat-
ments: placebo (open triangles); terfenadine (cloeed triangles); 
rofen (open circles); and flurbiprofen plus terfenadine (closed circlet). 
Each point represents the mean:i:sBM for 8 asthmatic subjects. FEV1 forced expiratory volume in one second. 
Results 
When compared to oral placebo, the mean baseline 
FEV1 values increased by 13.4% and 16.3% after terfenadine alone and the combination of active drugs 
respectively, while after flurbiprofen alone the mean 
increase was only 2.9% (table 2). Analysed as 4 groups 
by 2-way ANOV A, these changes were statistically 
insignificant 
The volume of room air inhaled and the calculated 
respiratory heat exchange during the exercise tests were 
not significantly different on any of the study days (table 
3). The mean calculated water loss ±sEM during exercise 
was 7.0±0.5 mls following placebo, 7.2±0.6 mls 
following terfenadine, 6.4±0. 7 mls following 
flurbiprofen, and 6.9±0.3 mls following the combination 
(NS). 
With each of the 3 drug treattnents and placebo, the 
exercise task produced falls in FEY 1 reaching a mean maximum fall 5 min post-exercise on the placebo and 
flurbiprofen days, and a mean maximum fall 10 min 
post-exercise when terfenadine or the drug combination 
had been given (fig. 1). After oral placebo, the fall in 
FEV1 remained depressed below baseline at 30 min, with a mean percentage fall of 20±4% at that time (fig. 1). 
Terfenadine alone reduced the post-exercise fall in FEV1 expressed as a percentage of pre-exercise baseline (table 
4). The inhibitory effect of terfenadine was most 
apparent in the first 5 min post-exercise and was 
negligible by 30 min. For the group as a whole, 
terfenadine reduced the mean maximum percentage fall 
in FEV1 by 34±11% (range -6%-85%) (p<0.05). When 
Table 4.- Maximum percentage falls in FEV, after exercise pre-study 
and following each drug treatment 
Treabnents 
Subjects Pre-study Placebo Terfenadine Flurbiprofen Combination 
1 54 49 48 25 36 
2 46 49 28 36 37 
3 44 50 10 25 4 
4 33 12 11 5 8 
5 34 29 10 16 26 
6 32 32 17 35 39 
7 43 44 46 39 51 
8 43 44 29 36 38 
Mean 41 39 25 27 30 
SBM 3 5 6 4 6 
FEV1: forced expiratory volume in one second. 
by subtracting the absolute response after the active drug 
from that after placebo, and expressing the percentage 
inhibition as a function of time. Least squares linear 
regression was used to examine the relationship between 
baseline spirometry and bronchoconstrictor response 
expressed as the AUC. 
analysed for the whole response between 0-30 min and 
compared to placebo, the mean AUC was reduced by 
32% after terfenadine (p<O.O (table 5). 
Flurbiprofen alone also inhibited the post-exercise fall 
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FIGURE 1. Airway responses to a variety of inhaled bronchoconstrictor mediators in one 
asthmatic subject. The relative potency of the mediators differ, with the cysteinyl leukotrienes 
and the thromboxane mimetic U46619 being the most potent studied to date in human subjects. 
relied on th  collecti n of various types of evidence. Generally, when t e structure 
of the mediator is identified and the mediator is synthesized, the mediator is given 
(usually by inhalation) to asthmatics to identify whether it can mimic some component 
of the asthmatic response. Subsequently, when assays for its measurement are avail- 
able, efforts are made to measure it in biological fluids to determine whether it is 
released (and excreted) during asthmatic responses. Then, when selective antagonists 
or synthesis inhibitors are available, efforts are made to block components of the 
asthmatic responses in clinical models of asthma. The final, and most difficult, hurdle 
is to determine whether the mediator antagonists or synthetase inhibitors are useful 
in treating asthmatic patients, thereby proving that the mediator has an important 
role in its pathogenesis. Each of these steps has been taken with the cysteinyl 
leukotrienes in asthma; the evidence that they are important in the pathogenesis of 
asthma will be reviewed. 
INHALED CYSTEINYL LEUKOTRIENES IN HUMAN SUBJECTS 
The cysteinyl leukotrienes were initially demonstrated to be very potent constric- 
tors of human airway smooth muscle in vitro.” The first report of the effects of 
inhaled LTC, and LTD4 in vivo was published in 1981 by Holroyde et aLI6 who 
demonstrated that these mediators caused bronchoconstriction in normal human sub- 
jects. Subsequently, inhaled LTC4 and LTD, have been demonstrated to be potent 
bronchoconstrictors in both normal and asthmatic subjects‘”lg (FIG. l), being up to 
10,OOO times more potent than methacholine in some normal subjects.’* The cysteinyl 
leukotrienes have also b en emonstrated to have a lo ger duration of action than 
inhaled hi~tamine.’~ The bronchoconstrictor effects of inhaled LTD4 are generally 
resolved within 1-2 hours, but are n t followed by t  d velopment of a late phase 
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Figure1. The fall in FE'" after exercise over time after treatment with in-
haled placebo (open circles) or PGE2 (closed circles). PGE2 significantly
attenuated the magnitude of exercise bronchoconstriction and shortened
the recovery time.
the time of the final measurement was used in the analysis. Results
are expressed as arithmetic means and SEM.
Methacholine PC20 values were log,o transformed prior to analysis,
results being expressed as geometric means and percent standard error
of the mean (% SEM). Two-tailedt tests for paired comparisons were used
to examine differences between placebo and PGE2 inhalation on base-
line FE'" measurements, maximal heart rate (HR), and ventilation/min
achieved during exercise, percent fall in FEV1 after exercise, AUC, time
to recovery, and airway responsiveness. The relationship between the pro-
tection achieved against exercise bronchoconstriction and methacholine
airway responsiveness was examined using Pearson'scorrelation. A value
of p<0.05was accepted as indicating statistical significance. The statistical





















Inhaled PGE2 significantly reduced exercise bronchoconstriction
(Figure 1).The mean maximal %fall in FE\4 following exercise was
26% (SEM 3.7%) after placebo treatment, and 9.7% (SEM 2.7%)
after PGE2 pretreatment (p <0.001). The degree of protection af-
forded by PGE2 varied among the subjects, ranging from 31.2%
to 100% inhibition (Table 1),and was a mean 66.2% for the whole
group. The subjects were selected to have> 15% fall in FE\!, af-
ter exercise on the screening day; however, after placebo treat-
ment two subjects had < 15% fall in FEV, after exercise. If these
two subjects are excluded from the analysis, the maximal %fall
in FEV; following exercise was 30.6% (SEM 2.4%) after placebo
treatment, and 12.5% (SEM 2.7%) after PGE2 pretreatment (p =
0.002). The degree of protection afforded by PGE2 for the sub-
jects with> 15% fall in FEV1 was 58.7%. The degree of protection
was not related to the degree of initial bronchoconstriction. The
magnitude of exercise bronchoconstriction as assessed by AUC
was also significantly attenuated by PGE2 treatment from 416.7
(SEM 115.8) after placebo to 154.4 (SEM 69.7) after placebo (p =
0.009); as was the mean time to recovery to within 5% of baseline
FEV;values after exercise, being 34 min (SEM 6.0)after placebo,
and 22 min (SEM 5.4) after PGE2 (p = 0.03). All subjects devel-
oped very transient bronchodilation immediately after exercise,





Methacholine inhalation challenge was performed as described by Cock-
croft and coworkers (16).Briefly, subjects inhaled normal saline and then
doubled concentrations of methacholine phosphate from a Wright nebu-
lizer, for 2 min. FE'" was measured at 30,90, 180, and 300 s after each
inhalation. The test was conducted until a fall in FE'" 20% of the base-
line value occurred. The provocative concentration causing a 20% fall
in (PC20) was recorded.
PGE2and Placebo Inhalation
PGE2 solution was prepared from a dry powder (Sigma Chemical Co.,
St. Louis, MO) by diluting in ethanol to obtain a 2 mg/ml stock solution,
and freezer-stored. On the appropriate study day, saline 1.2ml was added
to this stock solution to obtain a 1.67mg/ml solution of PGE2 • The solu-
tion was delivered using a breath-activated dosimeter (P.K. Morgan Ltd,
Gillingham, Kent, UK) set to produce an output of 0.006 ml (10 I-lgPGE2)
per breath. Subjects were instructed to take 10 deep breaths of the aero-
solized solution, for a total dose of 100 I-lg.A solution of 1.0 ml ethanol
in 1.2 ml saline was used as placebo. Inhaled PGE2 can cause cough;
for this reason the inhalation of PGE2 or placebo was conducted in a differ-
ent room and by a different investigator than the exercise or methacho-
line challenges.
Analysis
Bronchoconstriction after exercise was expressed as the maximal per-
cent fall in FE'" from the baseline value, which was the value measured
just prior to exercise, 30 min after inhalation of either placebo or PGE2 •
The area under the time-response curve (AUC) was calculated from
values recorded during the first 30 min postexercise. Duration of exercise
bronchoconstriction was examined by measuring the time to recovery to
within 5% of baseline In subjects in whom did not return to
within 5% of the baseline value, a conservative approach was taken, and
Study Design
Subjects were studied on 5 separate days, each at least 48 h apart. The
first day was a screening day during which subjects' characteristics were
documented, and an incremental exercisetest was performed as described
by Jones (15)to document the subjects' maximal work capacity and the
presence of exercise bronchoconstriction. The bronchoconstrictor re-
sponse to exercise was measured as the %fall in FE'" from baseline.
During the next 4 study days, baseline spirometry was measured and
subjects were pretreated with either inhaled PGE2 (diluted in ethanol and
saline) or placebo (ethanol in saline alone), delivered in a double-blind
randomized fashion. Spirometry was repeated 30 min later, and subjects
then underwent an exercise challenge or methacholine challenge.
Exercise Challenge
SUbjects exercised on a stationary bicycle ergometer (Ergomed 740; Sie-
mens Actiengesellschaft Medical Division, Erlangen, Germany), for 5 min
at a constant workload, selected on the screening day to increase the
heart rate to 80% predicted maximal heart rate. Subjects wore nose clips
and breathed dry air (0% relative humidity) at room temperature (20 to
230 C) from a Douglas bag reservoir, through a mouthpiece connected
to a 3-way Hans Rudolph valve. During the exercise, ventilation was mea-
sured by a dry-gas meter (MMC Horizon System; Sensormedics Co., Ana-
heim, CAl; heart rate was monitored continuously, and blood pressure
was measured every minute. FEV1 values were measured 30 min after
the inhalation of PGE2 or placebo, immediately before exercise, and then
immediately and 1, 3, 5, 8, and 10 min after exercise, and every 5 min
thereafter until it returned within 5% of baseline, or for a maximum of
60 min. The lowest FEV1 value was compared with the baseline value im-
mediately before exercise, to document the maximal fall in FEV. Spiro-
metric measurements were made using aCollins 4L water spirometer (Col-
lins Inc., Braintree, MA).
the duration of functional antagonism of short-acting inhaled bronchodi-
lators (14), to avoid caffeinated drinks during the study period, and not
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Histamine provocation 
At least 1 week before exercise challenge, a bronchial
challenge with histamine (histamine diphosphate was pre-
pared by the hospital pharmacy) was performed as des-
cribed previously [34]. In brief, histamine was inhaled
from a jet nebulizer equipped with a dosimeter (Spira
Electro 2; Respiratory Care Center, Hämeenlinna, Finland).
Pulmonary function was monitored on a vitalograph as
FEV1. The dose of histamine was increased by approxi-
mately half a log order of magnitude every 2 min until
FEV1 had decreased by 20% or more.
Enzyme immunoassay
Enzyme immunoassay analyses of (EIA) 9α,11β-PGF2
and LTE4 were performed in unextracted urine samples
with polyclonal antisera and acetylcholinesterase-linked
tracers (Cayman Chemical, Ann Arbor, MI, USA; Cas-
cade Biochem, Reading, UK). The concentration of each
sample was determined from a standard curve ranging
from 7.8–1000 pg·mL-1. The precision of the EIA for 9α,
11β-PGF2 [35] and LTE4 [36] is 9.7% and 17.6%, respecti-
vely. Crossreactivity of the 9α,11β-PGF2 antibody against
an array of related compounds has been tested previously
[34] and was: PGD2, 1.7%; PGF2α, 1.7%; 8-epi-PGF2α,
<0.01%.
Radioimmunoassay
Measurements of urinary Nτ-methylhistamine were    per-
formed with a commercial double-antibody radioimmu-
noassay (Pharmacia AB, Uppsala, Sweden). The concen-
tra-tion of Nτ-methylhistamine in the sample was deter-
mined from a standard curve ranging from 0–10 µg·L-1.
Samples exceeding these concentrations were subse-
quently diluted to ensure that they fell within the standard
curve. The de-tection limit for the assay was 0.1 µg·L-1, as
stated by the manufacturer, and the crossreactivity of the
antiserum with closely related compounds was as follows:
histamine, 5.6%; serotonin, 0.003%; histidine, 0.0005%.
The precision of the radioimmunoassay for Nτ-methylhis-
tamine was 8.8%. Concentrations of Nτ-methylhistamine
are express-ed as µg·mmol creatinine-1.
Statistical analysis
Calculations of geometric mean values of the pro-
vocative dose causing a 20% fall in FEV1 (PD20) were
performed on log-transformed raw data. Exercise bron-
choconstriction was determined as the maximal percent-
age change in FEV1 from baseline. All data are presented
as mean±SE unless otherwise stated. Differences in the
excretion of urinary mediators were compared by an un-
paired Student's t-test and considered significant if the
p-value was <0.05. The statistical calculations were per-
formed with the use of a validated statistical software
package for personal computers (Sigma Suite™; Jandel
Scientific, Sausalito, CA, USA).
Results 
Seven of the 12 subjects experienced a decrease of
Š15% in their FEV1 values following 5 min of exercise at
80% of maximum workload (responders). The mean±SE
maximal fall in FEV1 in the responder group was 23.0±
8%, with the peak bronchoconstriction occurring 15 min
after completion of exercise (fig. 1). In contrast, the FEV1
values for five of the subjects (nonresponders) remained
stable after exercise, with a maximal drop of not ð4±0.9%
from the pre-exercise baseline (fig. 1). The subject charac-
teristics of the responder and nonresponder groups did not
differ significantly from each other (table 1) although
PD20 values for histamine were slightly higher amongst
the responder group.
The mean urinary levels (ng·mmol creatinine-1) of 9α,
11β-PGF2, Nτ-methylhistamine and LTE4 before exercise
























Fig. 1.  –  Mean (±SEM) time course of forced expiratory volume in one
second (FEV1) values (% change from baseline) for the responders (●)
and nonresponders (❍) following exercise challenge. Pulmo ary func-
tion was measured before exercise, at 1, 3, 5, 8 and 10 min after exercise
























Fig. 2.  –  Mean (+SEM) urinary excretion of 9α,11β-prostaglandin
(PG)F2 in the responder (       ) and nonresponder (       ) groups after 5
min of exercise. *: p<0.05, significant increase in levels of 9α,11β-
PGF2 in the responder group at 30 and 90 min compared with the nonre-
sponders at the sam  time points. The concentration of 9α,11β-PGF2 in












































and 16 times elevated levels respectively (Fig. 1A).
Furthermore, significantly higher levels of LTC4 were
found at 0.7 M and 1.0 M mannitol with 4 and 10 times
increased release compared with the baseline value of 0.02
(0.02, 0.03) pmol/106 cells (Fig. 1B). Hyperosmolar sti-
mulation with mannitol also led to elevated levels of
released histamine compared to unstimulated cells 8 (2)
[mean (SEM)]% of total (Fig. 1C). Significantly increased
release of histamine was documented at 0.7 and 1.0 M
mannitol with nine- and sevenfold increases compared
with unstimulated cells respectively. For the following
experiments 0.7 M mannitol was chosen as hyperosmolar
stimulus. Mannitol (0.3–1.0 M) was not cytotoxic as no
LDH could be detected in supernatants from mannitol-
stimulated cells.
IgE-dependent release
Cells, passively sensitized with human myeloma IgE
(ND) (1 lg/ml) cross-linked with increasing doses of
anti-k (0.2–200 lg/ml), dose dependently released PGD2,
LTC4 and histamine. As controls, release of PGD2 and
LTC4 was also analysed from cells stimulated with anti-k
without prior sensitization as well as from sensitized cells
without the addition of anti-k. No increased release of
any mediator could be detected in these control samples
compared with unstimulated cells (data not shown). The
release of PGD2 at baseline was 0.7 (0.6, 0.8) pmol/10
6
cells and the amounts were significantly increased at 0.2,
2.0, 20 and 200 lg/ml anti-k to 29-, 65-, 88-and 55-times
enhanced levels respectively. IgE-mediated activation
further resulted in a dose-dependent generation of
LTC4 compared with unstimulated cells [0.02 (0.01,
0.02) pmol/106 cells]. Stimulation with increasing doses
of anti-k (0.2–200 lg/ml) elicited significantly elevated
amounts of LTC4 with 55-, 220-, 570- and 2300-fold
increase respectively (Fig. 2). For comparison, dose-
dependent release of histamine after anti-k stimulation
was analysed in two experiments. Under non-stimulated
conditions 6.7 (4.9, 8.6)% of total histamine was
released. Increasing doses of anti-k (0.2–200 lg/ml)
elicited more histamine, the increases were 1.1, 1.9, 2.5-
and 2.8-fold basal level respectively. Data for 200 lg/ml
anti-k was obtained from duplicate experiments and are
thus not shown in the figure. For the following
experiments challenge with 2 lg/ml anti-k was used for
activation.
Stimulus-dependent release
The mediator release pattern was compared after stimu-
lation with anti-k (2.0 lg/ml) in sensitized cells, mannitol
(0.7 M) or a combination of both. The amounts of PGD2
produced at baseline was 0.3 (0.2, 1.0) pmol/106 cells
Figure 1. Release of PGD2 (A), LTC4 (B) and histamine (C) after increasing doses of mannitol. Values in (A) and (B) are presented as
median (25th, 75th percentile) and in (C) as mean (SEM) from five and three individual experiments (n ¼ 9–12 and n ¼ 5–6
respectively). **P < 0.01, ***P < 0.001 when compared with control level or as indicated.
Figure 2. Release of PGD2 (square) and LTC4 (circle) after
increasing doses of anti-k. Values are presented as median (25th,
75th percentile) from four different experiments (n ¼ 8–10).
*P < 0.05 when compared with control level.
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mum fall in FEV1 after exercise challenge (r2! 0.008, p! 0.662).
However, the induced sputum volume was associated with the
severity of EIB (r2! 0.156, p! 0.051) and a trend was observed
between the total number of lower airway cells in induced spu-
tum and the severity of EIB (r2! 0.105, p! 0.115). No relation-
ship was seen between baseline lung function (r2 ! 0.056, p !
0.25) or bronchodilator response (r2 ! 0.094, p ! 0.13) and the
severity of EIB.
Effects of Exercise Challenge on Airway
Inflammatory Mediators
Effects of exercise challenge on airway cells and mediators were
assessed by comparing induced sputum samples obtained at
baseline and 30 minutes after exercise challenge during the ad-
ministration of placebo. The induced sputa at baseline and during
placebo administration were conducted an average of 9.9 days
apart (range, 4–18 days). There were no differences in induced
sputum volume (median 4.69 ml vs. 4.45 ml, p ! 0.17) and
concentration of lower airway cells in induced sputum (median
1.24 " 106 cells/ml vs. 1.53 " 106 cells/ml, p ! 0.82) between the
baseline and post-exercise samples. Therewas a significant increase
in the concentration of columnar epithelial cells and trends toward
decreased concentrations of lymphocytes and macrophage in
induced sputum after exercise challenge (Figure 2). No changes
were observed in the concentration of neutrophils (median 4.6 "
105 vs. 4.5 " 105, p ! 0.64) or eosinophils (median 2.5 " 104 vs.
2.2 " 104, p ! 0.56) after exercise challenge. There was a sig-
nificant increase in the percentage of columnar epithelial cells
(median 5.3% vs. 13.7%, p ! 0.001) and significant decreases
in the percentage of macrophages (median 41.3% vs. 28.0%,
p ! 0.01) and lymphocytes (median 1.6% vs. 1.2%, p ! 0.05).
No changes were observed in the percentage of neutrophils
(median 42.3% vs. 41.3%, p ! 0.78) or eosinophils (median
2.4% vs. 1.6%, p ! 0.72) after exercise.
The levels of histamine, tryptase, and CysLTs increased in
induced sputum after exercise challenge, whereas PGE2 and
TXB2 decreased after exercise challenge (Figure 3). The ratio
of CysLTs to PGE2 increased from a median of 3.87 at baseline
to 7.54 after exercise challenge (p ! 0.002). The concentrations
of CysLTs and histamine in induced sputum were associated
with the concentration of epithelial cells in induced sputum after
exercise challenge (Figure 4). There was a trend toward an asso-
ciation between the increase in CysLTs in induced sputum and
the severity of EIB measured by the AUC15 (r2 ! 0.133, p !
0.15). The levels of LTB4, IL-6 (19.3 vs. 26.1 pg/ml, p ! 0.14),
Figure 2. Effects of exercise challenge on the concentrations of columnar epithelial cells (a ), lymphocytes (b ), and macrophages (c ) in persons
with asthma and EIB. Comparisons were made between baseline and 30 minutes after exercise separated by an average of 9.9 days (range, 4–18
days). The box plots show the median (line), interquartile range (box), and the 10th and 90th percentiles (whiskers).
IL-8 (1,007 vs. 1,528 pg/ml, p ! 0.55), and vascular endothelial
growth factor (380.9 vs. 594.9 pg/ml, p ! 0.43) were no different
compared with baseline after exercise challenge. The levels of
IL-4, IL-5, IL-13, RANTES, and tumor necrosis factor-# were
below the level of detection in the majority of the subjects.
Treatment Effects on Lung Function and Severity of EIB
Before exercise challenge, there was modest improvement in
FEV1 (3.50 L versus 3.33 L, p ! 0.008) during treatment with
montelukast and loratadine as compared with matched placebo.
The severity of EIB was markedly attenuated by treatment with
montelukast and loratadine as seen by a 62% reduction inAUC15
during the first 15 min after exercise challenge (138.3 vs. 363.8,
p $ 0.001) and a 53.7% reduction in the maximum fall in FEV1
after exercise (%13.6% versus %29.3%, p $ 0.001) (Figure 5).
Symptoms of dyspnea after exercise were reduced at all time points
after exercise challenge during treatment (p $ 0.01) (Figure 6).
Treatment Effects on Airway Events During EIB
Effects of treatment with montelukast and loratadine on airway
cells and mediators were assessed by comparing induced sputum
samples obtained 30 minutes after exercise challenge during the
administration of placebo and during treatment with montelu-
kast and loratadine. The placebo- and treatment-induced sputa
were conducted an average of 6.8 days apart (range, 4–14 days).
There were no differences in induced sputum volume (median
4.45 ml vs. 4.33 ml, p ! 0.49) and concentration of lower airway
cells in induced sputum (median 1.53 " 106 cells/ml vs. 1.11 "
106 cells/ml, p ! 0.17) between the postexercise samples during
placebo and treatment. The concentration of lymphocytes was
decreased in induced sputum after exercise challenge during treat-
ment with montelukast and loratadine as compared with placebo
(median 1.57 " 104 cells/ml vs. 0.79 " 104 cells/ml, p ! 0.02).
The concentrations of eosinophils (median 2.16 " 104 cells/ml
vs. 2.01 " 104 cells/ml, p ! 0.37), macrophages (median 3.69 "
105 cells/ml vs. 3.02" 105 cells/ml, p! 0.53), neutrophils (median
4.46" 105 cells/ml vs. 4.36" 105 cells/ml, p! 0.55), and columnar
epithelial cells (median 1.47 " 105 cells/ml vs. 1.59 " 105 cells/ml,
p ! 0.56) in induced sputum after exercise challenge were no
different during placebo as compared with treatment with mon-
telukast and loratadine. There were no differences in the per-
centages of eosinophils (median 1.63% vs. 1.78%, p ! 0.28),
lymphocytes (median 1.18% vs. 0.91%, p ! 0.10), macrophages
(median 28.00% vs. 26.42%, p ! 0.23), neutrophils (median
41.27% vs. 40.58%, p ! 0.68), and columnar epithelial cells
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were asked to clear saliva from their mouth and then expectorate
sputum. The induced sputum was placed on ice and processed within
30 minutes. The sample was dispersed with an equal volume of DTT
0.1% in a shaking water bath at 37!C for 15 minutes. Total cell count
was determined with a hemocytometer, and slides for differential cell
counts were prepared with a cytocentrifuge. Slides were stained and
at least 400 nonsquamous cells counted per slide. A portion of the
supernatant was treated for eicosanoid analysis by the addition of 4
vols of methanol, precipitated, ce trifuged at 300 " g for 20 minutes,
evaporated to near dryness at 0.7 mmHg, and resuspended in methanol
and distilled water (20). The concentrations of mediators were deter-
mined by ELISA for histamine, tryptase, CysLTs, LTB4, PGE2, and
thromboxane B2. The concentrations of interleukin (IL)-4, IL-5, IL-6,
IL-8, tumor necrosis factor-#, RANTES (regulated upon activation,
normal T-cell expressed and secreted), and vascular endothelial growth
factor were determined by protein multiplex assay, and the concentra-
tion of IL-13 was determined by ELISA (additional details in the online
supplement).
St tistical Analysis
Charact ristics of the tudy participants were expressed as the mean
and standard deviation. The area under the FEV1/time curve (AUC)
(21) quantified the severity of EIB ove 0 to 30 minutes after exercise
(AUC30) during the screening visit and over 0 to 15 minutes after
exercise (AUC15) during the subsequent study visits. An ANOVA
model was used to ass ss the effe ts of treatment and determine if
there were carry over effects of treatment according to the sequence of
randomization. The medians of differential cell counts were compared
between different conditions with the Wilcoxon signed-rank test. The
levels of inflammatory mediators in induced sputum were compared
between different conditions with a paired t test of the log-transformed
values. The relationship of cellular constituents and inflammatory medi-
ators to each other and to severity of EIBwas assessed after log transfor-
mation using Pea son’s correlation coefficient.
RESULTS
Subject Characteristics
One hundred eleven potential participants with physician-
diagnosed asthma were screened for this study. Four subjects
were excluded because baseline FEV1 was less than or equal to
65% predicted. One hundred seven subjects had an exercise
challenge test; this identified 28 subjects with fall in FEV1 of
15% or more after exercise challenge. One subject was not en-
tered into the study because symptoms after exercise challenge
required $2-agonist treatment. Two participants were excluded
from the study because of time constraints or noncompliance.
A total of 25 patients with mild to moderate asthma who had
fall in FEV1 of 15% or more after exercise challenge completed
this study and were included in the analysis (Table 1). Twenty-
one of the 25 participants had mild asthma, with a baseline
FEV1 greater than or equal to 80% of predicted and symptoms
primarily during exercise. The severity of EIB ranged from a
maximum decline in FEV1 of 15% to 63% after exercise chal-
lenge during the screening visit. The average time between the
screening exercise challenge and the baseline induced sputum
was 14.7 days (range, 4–61 days). The intraclass correlation coef-
ficient for the severity of EIB measured by the AUC15 on the
screening day compared with the the AUC15 on the placebo visit
was 0.843 (p % 0.0002). The screening and placebo visits were
conducted on average 24.2 days apart (range, 11–69 days).
Characteristics of Airway Inflammation in EIB
The median percentage of lower airway cells at baseline were
2.4% eosinophils, 1.6% lymphocytes, 41.3% macrophages,
4 .3% n utrophils, and 5.3% columnar pithelial cells. Airway
eosinophilia greater than or equal to 2% was present in 14 of
25 and greater than or equal to 4% in 4 of 25 subjects. There was
no relationship between the percentage of airway eosinophils,
TABLE 1. CHARACTERISTICS OF STUDY PARTICIPANTS










FEV1, % 84.8 & 8.4
FVC, % 100.1 & 10.3
FEV1/FVC 0.78 & 0.06
FEF25–75, % 78.5 & 19.2
Postbronchodilator
' FEV1, % 11.0 & 6.2
' FVC, % 2.5 & 6.1
' FEV1/FVC, % 9.05 & 5.5
' FEF25–75, % 33.3 & 16.8
Postexercise
Maximum decrease in FEV1 29.2 & 11.9
Area under FEV1 curve* 681.4 & 321.5
Definition of abbreviation: EIB % exercise-induced bronchoconstriction.
Values reported are mean & SD unless otherwise specified.
* Area under the FEV1 curve over the first 30 min after exercise (% change · min).
neu rophils, lymphocytes, or macrophages in the baseline in-
duced sputum and the severity of EIB as measured by the maxi-
mum decline in FEV1 after exercise challenge during the placebo
visit. Similarly, there was no relationship between the concentra-
tion of eosinophils, neutrophils, lymphocytes, or macrophages
in the baseline induced sputum and the maximum fall in FEV1
after exercise challenge. The percentage of columnar epithelial
cells at baselinewas associatedwith the severity ofEIBmeasured
by the maximum fall in FEV1 after exercise challenge (r2 %
0.174, p % 0.043; Figure 1). A trend was noted between the
concentration of columnar epithelial cells in induced sputum
and the maximum fall in FEV1 after exercise challenge (r2 %
0.135, p % 0.077). The concentration of lower airway cells in
induced sputum (i.e., excluding squamous epithelial cells) was
not associated with the severity of EIB measured by the maxi-
Figure 1. Relationship between the percentage of columnar epithelial
cells in induced sputum at baseline and the severity of exercise-induced
bronchoconstriction (EIB) as measured by the maximum fall in FEV1











































































The tenascin-specific immunoreactivity band in the BM was

















m; 7.2 to 10.8 
 
mm,
p , 0.001) than in controls (mean: 0.8 mm; IQR 0 to 3.1 mm).
When analyzed according to BHR, tenascin expression was in-
creased in the order: controls , nonhyperresponsive skiers ,
hyperresponsive skiers , mildly asthmatic subjects. Tenascin
expression in nonhyperresponsive skiers was not significantly
different than in hyperresponsive skiers (Figure 6). On sub-
group analysis according to nonatopic status, tenascin expres-
sion was found to be significantly greater in skiers (mean 6.5 mm;
IQR: 5.2 to 7.5 mm, p , 0.001) and asthmatic subjects (8.8 mm;
IQR: 7.2 to 9.7 mm, p , 0.001) than in controls.
Correlations
In skiers, the T-lymphocyte count correlated significantly with
counts of mast cells (n 5 40, r 5 0.33, p 5 0.04) and macroph-
ages (n 5 40, r 5 0.5, p 5 0.001). Skiing experience in years
was significantly correlated only with the macrophage count
(n 5 40, r 5 0.42, p 5 0.007). There were no significant corre-
lations of cell counts with tenascin immunoreactivity. Cell
counts and tenascin were not significantly correlated either
PD20 FEV1 or with bronchial responsiveness.
DISCUSSION
In this study, we observed a mucosal inflammatory cellular in-
filtrate and increased subepithelial tenascin deposition in the
proximal airways of young, competitive cross-country skiers.
Although no skier had a known medical diagnosis of asthma,
the possibility of undiagnosed asthma cannot be excluded,
since asthmalike symptoms and use of b2-agonists were re-
ported by 65% and 15% of the skiers, respectively. However,
the degree of cellular infiltration in the skiers was different in
several respects from that observed in steroid-naïve subjects
with mild asthma. With the exception of T lymphocytes, skiers
had a lesser degree of infiltration with eosinophils, mast cells,
and macrophages. Moreover, skiers had a greater degree of
neutrophil infiltration, which is not a significant feature in ei-
ther atopic or nonatopic asthma (16, 17), suggesting that the
inflammatory process in these athletes is different from that in
asthmatic individuals.
The changes observed in the skiers in our study contrast
with the absence of inflammatory changes in bronchial biopsy
specimens from clinically healthy, asymptomatic sportsmen as
reported by Power and associates (18). Moreover, Power and
associates did not observe hyperresponsive subjects in their
study, whereas in the present study, inflammatory changes
were observed in hyperresponsive as well as in nonhyperre-
sponsive athletes. We do not know why nonhyperresponsive
skiers have inflammatory changes in their airways, but it is
possible that these changes are related to repeated exposure
of the proximal airways to inadequately conditioned air. Leu-
cokyte infiltration and epithelial injury have been demon-
Figure 4. Low-power transm ission electron m icroscopy image show-
ing postcapillary venules (V) in the lam ina propria in a large airway
specimen from a hyperresponsive elite skier. Many neutrophils (open
arrows) are seen in the venules (original magnification: 32,400). Bar 5
10 mm .
Figure 5. Low-power transm ission electron m icroscopic image of large
airways of a hyperresponsive subject. Some neutrophils (N) are present
in the abnormal airway epithelium (E). The BM is thickened (open ar-
rows), and many f ibrob lasts and lymphocytes are seen in the lam-
ina propria beneath the epithelium (original magnification: 32,400).
Bar 5 10 mm .
Figure 6. Thickness of tenascin immunoreactive band in subepithelial
BM zone in controls, skiers w ith and w ithout BHR, and asthmatic sub-
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ported by the fact that KL-6 is a member of the MUC1 gene
family, which is expressed in the lung, and by the behavior of
this antigen in serum, which correlates with ELF levels among
healthy subjects and increases markedly in several lung disor-
ders (227, 228, 292, 339). Even if different data suggest that
the lung is the major source of 17-Q2 and 17-B1 in the circula-
tion, the lung specificity of these mucin-associated antigens
has not been fully demonstrated.
EVIDENCE OF A LUNG–BLOOD 
BIDIRECTIONAL EXCHANGE
Although the lung–blood barrier has long been considered to
be impermeable to most macromolecules (357–363), this view
has been challenged by an increasing number of studies indi-
cating that small quantities of proteins may normally be trans-
located in both directions across the air–blood barrier. Since
Figure 1. Master Blot analysis of poly(A)1 RNA from various human tissues (Human RNA Master Blot; C lontech, San D iego, CA). For hy-
bridization, 32P-radiolabeled cD NA probes specific for CC16 (CC10), SP-A, SP-B, and b-actin (control probe) were used on the same
Northern blot. The expression of CC16, SP-A, and SP-B was confined mainly to respiratory tract tissues. Extrapulmonary synthesis has been
found in the prostate for CC16 and in the kidney for SP-A and CC16. In these tissues, the levels of expression average 20 times lower than


























































Fig. 7 A diagram indicating that, after denudation, epithelial restitution occurs speedily under the provisional cover of a plasma-
derived and leukocyte-rich gel. N=neutrophils; E=eosinophils.
until a new, flat, and tight epithelium has been es- pathophysiology, the cellular pathology and the struc-
tural changes (Fig. 8) that we now regard as char-tablished.65 Hence, migration of cells involved in the
restitution process occurs in close association with acteristic of asthmatic bronchi.55 Not only may
shedding-restitution evoke a secretory response andplasma-derived adhesive proteins such as fibronectin
and fibrin54 as well as other plasma- and leukocyte- a sustained plasma exudation process65 but epithelial
damage and repairwill also cause traYc and activationderived factors,9 including such growth factors that
may promote repair. The gel provides both a pro- of eosinophils9 with significantly increased numbers
of free eosinophil granules in themucosa (secondary tovisional cover and an appropriate supramembranal
milieu for the in vivo restitution process (Fig. 7). If prompt lysis and, non-apoptotic, death of eosinophils
which appears to be the in vivo paradigm of activationonly columnar cells are being shed the remaining
cobbled surface of basal cells will immediately change of these cells69 in asthma). There is accumulation and
activation of neutrophils.19 Furthermore, there areinto flattened basal cells that establish cell to cell
contact.67 Indeed, the flattened repair cells occurring several changes, beyond the epithelial disruption and
the occurrence of epithelial restitution cells, that maypromptly after epithelial shedding, whether the shed-
ding has produced denudation or loss of columnar be regarded as remodelling eVects.55 These include
epithelial metaplasia, thickened reticular basementcells only, would provide reduced junctional lengths
per unit mucosal surface area. It is thus suggested membrane, enlargement of regional lymph nodes, pro-
liferation of fibroblasts/smooth muscle cells and thethat the prompt appearance of poorly diVerentiated,
large flat cells together with the ensuing epithelial laying down of plasma-derived adhesive proteins as
extracellular matrix.55 Inferentially, it appears in-metaplasia may explain observations of reduced air-
way absorption in disease.20 In summary, abnormal creasingly important to protect the airway epithelium
from damage so that shedding/restitution-evoked pro-degrees of epithelial shedding and plasma exudation
may occur in airways which, nevertheless, exhibit cesses can be reduced to a minimum in asthma (Fig.
8).normal or even improved barrier functions.
Shedding-restitution as a cause of airway CONCLUSION
inflammation and remodelling
Animal studies in vivo indicate that shedding-repair The profuse airwaymucosalmicrocirculation has sev-
eral important functions in health and disease. Oneprocesses, by themselves, produce a series of physio-
logical and cellular responses in the airways. In health, of its major roles lies in the process of extravasation
and mucosal exudation of bulk plasma. This responsethese are functionally important and lead to repair and
homeostasis.68However, in disease, extensive epithelial is produced by allergic reactions, infectious processes,









































EVH, mannitol, AMP,47 or exercise.48 This raises the question as
to whether the AHR in cold-weather/dry-weather athletes is a re-
flection of airway injury rather than a sign of classical asthma. The
AHR in these winter athletes is also much milder than would be
expected in subjects with classical asthma.49 There are some sum-
mer athletes who also appear to have airway injury. Thus swim-
mers who train for long hours in irritant environments might
also have a high prevalence of reported AHR to methacholine.50,51
There are differences in the mode of action of the provoking
stimuli used to assess athletes. For example, the pharmacologic
agent methacholine acts directly on acetylcholine receptors to
cause bronchial smooth muscle contraction. The transient hyper-
osmotic effects of evaporative water loss or the inhalation of
hyperosmolar aerosols are not a direct stimulus to the smooth
muscle. Rather the hyperosmolar stimulus acts indirectly through
release of mediators from inflammatory cells (mast cells and
eosinophils) situated in or close to the airway surface. These
mediators, including PGD2, LTE4, and histamine, then act on re-
ceptors to cause contraction of the smooth muscle and narrowing
of the airways. The same mediators can increase vascular perme-
ability. Hyperosmolarity is a stimulus for epithelial cells to pro-
duce PGE2 and 15 hydroxyeicosatetraenoic acid (15 HETE)
and for neuronal cells to release tachykinins.52,53 Adenosine is
also released in response to hyperosmolarity.54 All these out-
comes help to restore the ASL toward normal ion concentration,
volume, and osmolarity.
Another unexpected finding was that the AHR in cross-country
skiers with symptoms of asthma was not improved by treatment
with inhaled steroids, a benefit well-described in asthmatic
subjects.55 Respiratory symptoms and airway responses only im-
proved after a reduction in workload during training, a finding in
keeping with less injury.55 An important and unexpected finding
was that montelukast provided greater protection against EIB
(90%) in a high-particulate-matter environment compared with
that seen in a low-particulate-matter environment (35%), suggest-
ing the response to the particulate matter is predominantly LT
mediated.56 Finally, an unexpected finding came from the Winter
Olympics in Turin. In those games only 32.1% of the athletes ap-
plying to use a b2-adrenoceptor agonist (b2-agonist) reported
asthma in childhood, and for 48.7% of them, the onset of asthma
or EIB occurred after 20 years of age, which is very unusual.57
PATHOGENESIS OF AHR AND EIB IN ATHLETES
In 2005, an hypothesis for the pathogenesis of EIB and AHR in
elite athletes was put forward (Fig 1).58 In brief, the hypothesis
proposed that when cold air was inspired at high flow, the epithelia
of the small airways recruited into the conditioning process would
become susceptible to dehydration injury. The response to this
epithelial injury would involve exudation of bulk plasma as part
of the restorative process.59,60 In elite athletes performing winter
sports, this process of epithelial injury and repair would be repeated
many times during the season (Fig 2).61 It was proposed that AHR
and EIB could develop for the first time58 as a result of changes in
the contractile properties of ASM after repeated exposure to
plasma-derived products.61,62 Thus cold-weather athletes could ex-
perience AHR to pharmacologic agents simply as a result of epithe-
lial injuryand repair. This conceptwas supported by the return to the
normal range of airway responsiveness out of season63 or after re-
tirement.64 Furthermore, this reversal of AHR suggests that airway
remodeling does not occur in response to this type of acute injury
and is likely not a predictor of chronic disease.65
For summer athletes, who are more likely to be atopic,66 have
rhinitis, and have higher than normal levels of circulating IgE, the
ASM would become ‘‘passively sensitized’’ in vivo as a result of
transient but repeated exposure to bulk plasma.58,67 The degree to
which this could happen would likely be related to circulating
levels of IgE.67,68
It had been known for several years that some athletes have an
increase in circulating levels of inflammatory mediators, such as
LTs and PGs, in response to exercise.69,70 Furthermore, mast cells
close to theASMhad beendescribed in the small airways of healthy
FIG 1. Flow chart describing the acute events leading to EIB in the subject with classic asthma (left) and the
events leading to the development of EIB in the athlete (right). Reproduced with permission from Anderson
SD,KippelenP.Exercise-inducedbronchoconstriction:Pathogenesis.CurrAllergyAsthmaRep2005;5:116-22.58
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Redrawn from Omori., JAP, 1995  















































































































































































































































Inspired and expired lung volumes measured by spirometry
are useful for detecting, characterising and quantifying the
severity of lung disease. Measurements of absolute lung
volumes, residual volume (RV), functional residual capacity
(FRC) and total lung capacity (TLC) are technically more
challenging, which limits their use in clinical practice. The role
of lung volume measurements in the assessment of disease
severity, functional disability, course of disease and response
to treatment remains to be determined in infants, as well as in
children and adults. Nevertheless, in particular circumstances,
measurements of lung volume are strictly necessary for a
correct physiological diagnosis [1].
In contrast to the relative simplicity of spirometric volumes, a
variety of disparate techniques have been developed for the
measurement of absolute lung volumes. These include the
following: body plethysmography (using various methodolo-
gies), nitrogen washout, gas dilution, and radiographic
imaging methods.
The present document integrates and consolidates the recom-
mendations of the current American Thoracic Society (ATS)/
European Respiratory Society Task Force on pulmonary
function standards, and the recommendations from an earlier
National Heart, Lung, and Blood Institute (NHLBI) workshop
convened by the ATS. The NHLBI workshop participants, who
were experts with considerable adult and paediatric experi-
ence, published their input in the form of background papers
in the European Respiratory Journal between 1995 and 1999 [2–
12]. Later, a NHLBI workshop consensus document was
written, which can be found on the ATS website [13], for
those who require more in-depth descriptions, discussion and
a fuller derivation of equations.
DEFINITIONS AND SUBDIVISIONS OF LUNG VOLUME
The term ‘‘lung volume’’ usually refers to the volume of gas
within the lungs, as measured by body plethysmography, gas
dilution or washout. In contrast, lung volumes derived from
conventional chest radiographs are usually based on the
volumes within the outlines of the thoracic cage, and include
the volume of tissue (normal and abnormal), as well as the
lung gas volume. Lung volumes derived from computed
tomography (CT) scans can include estimates of abnormal lung
tissue volumes, in addition to normal lung tissue volumes and
the volume of gas within the lungs. In this statement,
previously accepted definitions will be used (fig. 1) [14–18].
The FRC is the volume of gas present in the lung at end-
expiration during tidal breathing.
The expiratory reserve volume (ERV) is the volume of gas that
can be maximally exhaled from the end-expiratory level
during tidal breathing (i.e. from the FRC).
The maximum volume of gas that can be inspired from FRC is
referred to as the inspiratory capacity (IC).
The inspiratory reserve volume is the maximum volume of gas
that can be inhaled from the end-inspiratory level during tidal
breathing.
RV refers to the volume of gas remaining in the lung after
maximal exhalation (regardless of the lung volume at which
exhalation was started).
The volume of gas inhaled or exhaled during the respiratory
cycle is called the tidal volume (TV or VT).
The thoracic gas volume (TGV or VTG) is the absolute volume
of gas in the thorax at any point in time and any level of
alveolar pressure. Since this term is too nonspecific, it is
recommended that its use should be discontinued and
replaced with more specific terminology, for example,
plethysmographic lung volume (abbreviated at VL,pleth), and
FRC by body plethysmography or TGV at FRC (FRCpleth).
TLC refers to the volume of gas in the lungs after maximal
inspiration, or the sum of all volume compartments.
The vital capacity (VC) is the volume change at the mouth
between the positions of full inspiration and complete
expiration. The measurement may be made in one of the
following ways: 1) inspiratory vital capacity (IVC), where the
measurement is performed in a relaxed manner, without
undue haste or deliberately holding back, from a position of
full expiration to full inspiration; 2) expiratory vital capacity
(EVC), where the measurement is similarly performed from a
position of full inspiration to full expiration; or 3) forced vital
capacity, which is the volume of gas that is exhaled during a
forced expiration, starti g from a position of full inspiration
and ending at complete expiration.
PATIENT PREPARATION
Guidelines for patient preparation are included in the
statement on general c nsideratio s for lung function testing
in this series of documents [19].
DERIVATION OF LUNG SUBDIVISIONS
No matter what technique is used to measure FRC (see sections
entitled Measurement of FRC using body plethysmography,
Measurement of FRC using nitrogen washout, and
Measurement of FRC using helium dilution), two subdivisions
of the VC (IC and ERV) will have to be measured in order to
calculate the TLC and RV (fig. 1). It has proved difficult to
reach a consensus on whether the RV should be the minimal
value as would most probably be obtained by performing the
ERV manoeuvre from FRC and then subtracting ERV from the
measured value for FRC, or the approaches which would likely









FIGURE 1. Static lung volumes and capacities based on a volume–time
spirogram of an inspiratory vital capacity (IVC). IRV: inspiratory reserve volume; VT:
tidal volume (TV); ERV: expiratory reserve volume; RV: residual volume; IC:
inspiratory capacity; FRC: functional residual capacity; TLC: total lung capacity.
STANDARDISATION OF LUNG VOLUME MEASUREMENT J. WANGER ET AL.

























































































































































































































































































































































































































































































































































































































































































































































































% % Control% Euhydration% Dehydration%
FEV1$(l)$ Baseline$ 4.18$±$0.85$ 4.17$±$0.87$ 4.21$±$0.89$
10$min$post8exercise$ 4.28$±$0.90$ 4.20$±$0.96$ 4.24$±$0.90$
2$h$post8exercise$ 4.30$±$0.92$ 4.24$±$0.93$ 4.23$±$0.89$
Rehydration$(1$h$post8EVH)$ 4.10$±$0.81$ 4.10$±$0.90$ 4.19$±$0.94$
FVC$(l)$ Baseline$ 5.12$±$1.19$ 5.09$±$1.23$ 5.09$±$1.22$
10$min$post8exercise$ 5.10$±$1.17$ 5.00$±$1.21*$ 4.79$±$1.10*,C,E$
2$h$post8exercise$ 5.17$±$1.25$ 5.06$±$1.20$ 4.89$±$1.10*,C,E$
Rehydration$(1$h$post8EVH)$ 5.06$±$1.21$ 5.03$±$1.25$ 5.00$±$1.20*$
PEF$(l⋅s81)$ Baseline$ 9.20$±$2.10$ 9.12$±$2.12$ 9.13$±$2.25$
10$min$post8exercise$ 9.64$±$2.44$ 9.47$±$2.47$ 9.16$±$2.01$
2$h$post8exercise$ 9.62$±$2.32$ 9.36$±$2.31$$ 9.12$±$2.16$



























































# Control& Euhydration& Dehydration&
# Baseline# PostBrest## Baseline# PostBexercise## Baseline# PostBexercise#
FRC#(l)# 3.49#±#0.97# 3.55#±#1.02# 3.46#±#1.02# 3.35#±#0.95C# 3.40#±#0.99# 3.65#±#0.90*E#
RV#(l)# 1.77#±#0.55# 1.81#±#0.59# 1.76#±#0.45# 1.74#±#0.51# 1.73#±#0.46# 1.99#±#0.57*E#
ERV#(l)# 1.72#±#0.61# 1.74#±#0.66# 1.71#±#0.67# 1.61#±#0.56# 1.67#±#0.64# 1.67#±#0.48#
VC#(l)# 4.94#±#1.20# 4.91#±#1.18t# 4.96#±#1.17# 4.92#±#1.19t# 4.97#±#1.21# 4.75#±#1.12t#
TLCpleth#(l)# 6.72#±#1.66# 6.71#±#1.59# 6.72#±#1.55# 6.66#±#1.62# 6.70#±#1.58# 6.74#±#1.61#
TLCplethBTLChe#(l)# 0.09#±#0.64# 0.40#±#0.40
t# 0.26#±#0.58# 0.43#±#0.53t# 0.30#±#0.67# 0.61#±#0.48t#
DLCOc#(mmol⋅#minB1⋅kPaB1)# 10.16#±#2.87# 9.71##±#2.61# 9.92##±#2.69# 9.72#±#2.53# 10.14##±#2.81# 10.07##±#2.85#
KCOc#(mmol⋅#minB1⋅kPaB1⋅lB1)# 1.63##±#0.27# 1.57##±#0.25# 1.65##±#0.25# 1.60#±#0.22# 1.65##±#0.22# 1.63##±#0.20#
Raw$(kPa⋅s⋅lB1)$ 0.26#±#0.09# 0.24#±#0.07t# 0.28#±#0.09# 0.25#±#0.07t# 0.25#±#0.06# 0.25#±#0.06t#












































































































































































































































































































































































































Screening& Placebo& Terbutaline& Protection&(%)&
1$ M$ +$ 95$ Asthma$+$EIB$ Combination,$SABA$ 1600$ 17$ 18$ 15$ 17$
2$ M$ +$ 92$ Asthma$ SABA,$ICS$$ 200$ 50$ 13$ 5$ 62$
3$ M$ +$ 99$ Asthma$+$EIB$ Combination$ 400$ 16$ 12$ 18$ 0$
4$ F$ +$ 108$ EIB$ SABA,$ICS$ 200$ 21$ 13$ 12$ 8$
5$ M$ +$ 97$ D$ D$ D$ 16$ 15$ 4$ 73$
6$ F$ +$ 92$ Asthma$ SABA,$ICS$ 200$ 10$ 14$ 8$ 43$
7$ M$ +$ 93$ Asthma$+$EIB$ SABA$ D$ 23$ 21$ 8$ 63$
8$ M$ +$ 102$ Asthma$ SABA$ D$ 21$ 12$ 5$ 58$
9$ F$ +$ 93$ Asthma$ Combination$ 400$ 10$ 13$ 2$ 85$
10$ M$ +$ 99$ Asthma$ SABA,$ICS$ 600$ 36$ 26$ 25$ 4$
11$ M$ D$ 99$ D$ D$ D$ 11$ 11$ 6$ 45$
12$ M$ +$ 85$ Asthma$ D$ D$ 9$ 14$ 6$ 57$
13$ F$ +$ 103$ Asthma$ D$ D$ 27$ 29$ 9$ 69$
14$ M$ +$ 109$ EIB$ SABA$ D$ 14$ 11$ 7$ 36$
15$ F$ D$ 99$ Asthma$+$EIB$ Combination$ 400$ 19$ 16$ 7$ 56$
16$ F$ D$ 109$ D$ D$ D$ 12$ 20$ 11$ 45$
17$ M$ +$ 94$ Asthma$ SABA$ D$ 18$ 17$ 1$ 94$
18$ M$ D$ 85$ Asthma$ Combination$ 200$ 14$ 13$ 6$ 54$
19$ M$ +$ 109$ Asthma$+$EIB$ ICS$ 100$ 14$ 15$ 9$ 40$
20$ F$ D$ 96$ Asthma$ SABA$ D$ 12$ 10$ 8$ 20$
21$ M$ +$ 94$ Asthma$ SABA$ D$ 15$ 13$ 7$ 46$
22$ M$ +$ 111$ Asthma$ SABA,$ICS$ 200$ 16$ 16$ 1$ 94$
23$ F$ +$ 102$ EIB$ SABA,$ICS$ 200$ 23$ 28$ 6$ 79$
24$ F$ +$ 86$ Asthma$ SABA$ D$ 28$ 22$ 8$ 64$
25$ F$ D$ 88$ EIB$ D$ D$ 10$ 11$ 1$ 91$
26$ F$ +$ 82$ Asthma$+$EIB$ SABA$ D$ 46$ 47$ 6$ 87$
27$ M$ +$ 91$ Asthma$ SABA$ D$ 16$ 11$ 2$ 81$



























Placebo& $ $ $ $ $
$$$$$FEV1$(L)$ 3.68$±$0.65$ 3.67$±$0.67$ 3.06$±$0.68$ 0.316$ <0.001$
$$$$$FVC$(L)$ 4.74$±$0.93$ 4.76$±$0.95$ 4.48$±$1.04$ 0.798$ <0.001$
$$$$$FEF25D75$(Lbs
D1)$ 3.27$±$0.90$ 3.27$±$0.90$ 2.17$±$0.69$ 0.741$ <0.001$
$$$$$FEF25$(Lbs
D1)$ 6.18$±$1.23$ 6.12$±$1.23$ 4.39$±$1.30$ 0.495$ <0.001$
$$$$$FEF50$(Lbs
D1)$ 3.57$±$0.86$ 3.71$±$0.98$ 2.47$±$0.78$ 0.478$ <0.001$
$$$$$FEF75$(Lbs
D1)$ 1.70$±$0.90$ 1.63$±$0.58$ 1.02$±$0.39$ 0.866$ <0.001$
$$$$$PEF$(LbsD1)$ 8.15$±$1.48$ 8.15$±$1.44$ 6.45$±$1.65$ 0.968$ <0.001$
Terbutaline& $ $ $ $ $
$$$$$FEV1$(L)$ 3.65$±$0.64$ 3.82$±$0.68$ 3.43$±$0.63$ <0.001$ <0.001$
$$$$$FVC$(L)$ 4.74$±$0.94$ 4.73$±$0.95$ 4.62$±$0.95$ 0.796$ <0.001$
$$$$$FEF25D75$(Lbs
D1)$ 3.26$±$0.93$ 3.37$±$0.97$ 3.07$±$0.86$ <0.001$ <0.001$
$$$$$FEF25$(Lbs
D1)$ 6.15$±$1.32$ 6.78$±$1.41$ 5.57$±$1.32$ <0.001$ <0.001$
$$$$$FEF50$(Lbs
D1)$ 3.77$±$1.06$ 4.22$±$1.33$ 3.45$±$0.84$ <0.001$ <0.001$
$$$$$FEF75$(Lbs
D1)$ 1.62$±$0.61$ 2.16$±$1.43$ 1.47$±$0.50$ <0.001$ <0.001$












































































































































































































































































































































1$ M$ +$ 95$ Asthma$+$EIB$ Combination,$SABA$ 1600$
2$ M$ +$ 92$ Asthma$ SABA,$ICS$ 200$
3$ M$ +$ 99$ Asthma$+$EIB$ Combination$ 400$
4$ F$ +$ 108$ EIB$ SABA,$ICS$ 200$
5$ M$ +$ 97$ <$ <$ <$
6$ F$ +$ 92$ Asthma$ SABA,$ICS$ 200$
7$ M$ +$ 93$ Asthma$+$EIB$ SABA$ <$
8$ F$ +$ 93$ Asthma$ Combination$ 400$
9$ M$ +$ 99$ Asthma$ SABA,$ICS$ 600$
10$ M$ <$ 99$ <$ <$ <$
11$ M$ +$ 85$ Asthma$ <$ <$
12$ F$ +$ 103$ Asthma$ <$ <$
13$ M$ +$ 109$ EIB$ SABA$ <$
14$ F$ <$ 99$ Asthma$+$EIB$ Combination$ 400$
15$ F$ <$ 109$ <$ <$ <$
16$ M$ +$ 94$ Asthma$ SABA$ <$
17$ F$ <$ 96$ Asthma$ SABA$ <$
18$ M$ +$ 94$ Asthma$ SABA$ <$
19$ M$ +$ 111$ Asthma$ SABA,$ICS$ 200$
20$ F$ +$ 102$ EIB$ SABA,$ICS$ 200$
21$ F$ +$ 86$ Asthma$ SABA$ <$
22$ F$ <$ 88$ EIB$ <$ <$
23$ F$ +$ 82$ Asthma$+$EIB$ SABA$ <$

























































































































































































































































































































































































































































1$ M$ 102$ 117$ Asthma$ SABA$ B$ +$ 31$
2$ M$ 81$ 98$ Asthma$ B$ B$ +$ 14$
3$ M$ 78$ 102$ Asthma$ Combination$ 250$ +$ 17$
4$ M$ 93$ 107$ Asthma$ B$ B$ +$ 16$
5$ F$ 97$ 109$ Asthma$ Combination$+$
AntiBhistamine$
500$ +$ 14$
6$ F$ 90$ 116$ EIB$ SABA$ B$ +$ 19$
7$ M$ 101$ 120$ Asthma$ SABA$ B$ +$ 27$






























FEV1$(l)$ 3.69$±$0.67$ $3.63$±$0.61$ 3.67$±$0.66$ $2.84$±$0.45**$ P=0.852$ P$=0.002$
FVC$(l)$ 5.34$±$0.70$ 5.26$±$0.70$ 5.24$±$0.63$ 4.75$±$0.47**$ P$=0.301$ P$=0.005$
PEF$(l⋅sB1)$ 8.09$±$2.10$ 7.71$±$1.92*$ 8.09$±$1.92$ 6.68$±$1.54**$ P$=0.985$ P$=0.013$
FEV1/FVC$(%)$ 69$±$6$$ 68$±$5.67$ 70$±$7$ 59$±$6**$ P$=0.245$ P$=0.001$
FEF25B75$(l⋅s



































































































































































$ Baseline$ Peak$ Baseline$ Peak$
UPLC/MS/MS% $ $ $ $
PGD2% Not%measured% Not%measured% Not%measured% Not%measured%
$$$$$2,3BdinorBPGF2α$ 54$(31B76)$ 129$(42B136)*$ 64$(51B67)$ 74$(63B114)$
$$$$$TetranorBPGDM$ 313$(231B377)$ 299$(232B537)$ 391(236B457)$ 308$(212B700)$
PGE2% 9$(5B12)$ 15$(8B20)$ 10$(8B18)$ 12$(8B31)$
$$$$$TetranorBPGEM$ 1056$(768B1325)$ 1674$(1325B1871)*$ 1288$(696B1854)$ 2782$(992B5462)*$
PGI2% Not%measured% Not%measured% Not%measured% Not%measured%
$$$$$2B3BdinorB6ketoBPGF1α% 73$(32B130)$ 241$(170B318)*$ 131$(87B160)$ 198$(177B397)*$
TXB2$ 4$(3B6)$ 4$(3B10)$ 4$(4B5)$ 6$(4B7)$
$$$$$11BdihydroBTXB2$ 3$(2B4)$ 5$(4$–$9)*$ 5$(3B7)$ 6$(3B12)$
$$$$$2B3BdinorBTXB2$ 37$(26B39)$ 43$(36B90)*$ 44$(26B71)$ 65$(38B78)$
8"iso"PGF2α% 21$(18B37)$ 35$(25B42)$ 26$(21B30)$ 31$(21B47)$
$$$$$2,3BdinorB8BisoBPGF2α$$ 152$(103B186)$ 232$(166B267)*$ 142$(115B223)$ 275$(150$–$369)*$
$$$$$8,12BiPF2αBIV$ 447$(383B625)$ 754$(526B866)$ 461$(402B644)$ 735$(498B1202)$
ELISA% $ $ $ $
PGD2% Not%measured% Not%measured% Not%measured% Not%measured%
$$$$$11β$PGF2α$ 70$(64B87)$ 73$(66B84)$ 67$(57$–$84)$ 61$(61B83)$
LTE4$ 31$(19B50)$ 39$(24B55)$ 36$(14B114)$ 37$(19B57)$
Data$are$ngqµmol$creatinineB1$and$presented$as$median$and$interquartile$range$(Q1B
Q3);$*$P<0.05$vs.$baseline.$$





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































! the!School!of!Sport!&!Education,!Brunel!University.! ! !!







Name!of!Volunteer! ! Date! Signature!
!
_________________________! ________________! ____________________!























PRE-PARTICIPATION HEALTH CHECK QUESTIONNAIRE  
!
















2. Do!you!suffer!from!chest!pains!or!heart!palpitations?! ! ! Yes!/!No!
3. Do!you!have!known!high!blood!pressure?!! ! ! ! Yes!/!No!
4. Do!you!have!low!blood!pressure!or!often!feel!faint!or!have!dizzy!spells?! Yes!/!No!
5. Do!you!have!known!hyperFcholesteremia?! ! ! ! Yes!/!No!
6. Do!you!suffer!from!diabetes?!! ! ! ! ! ! Yes!/!No!




9. Do!you!commonly!cough,!get!wheeze,!get!short!of!breath,!feel! ! Yes!/!No!
tightness!in!your!chest!and/or!produce!a!lot!of!mucus!after!exercise?!
















11. Have!you!had!a!chest!infection!or!a!cold!in!the!last!4!weeks?! ! Yes!/!No!
12. Do!you!suffer!from!seasonal!allergy?! ! ! ! ! Yes!/!No!
If!so,!have!you!had!allergic!symptoms!in!the!last!4!weeks?! ! Yes!/!No!
13. Do!you!have!a!history!of!anaphylactic!shock?* * * * Yes!/!No!
14. Do!you!suffer!from!epilepsy?! ! ! ! ! ! Yes!/!No!
15. Are!you!taking!any!medication?!If!so,!please!list!below! ! ! Yes!/!No!
16. Are!you!taking!any!vitamins!or!health!supplements?!If!so,!please!list! Yes!/!No!
17. Do!you!have!any!injuries!that!cause!pain!when!exercising?! ! Yes!/!No!
18. !Are!you!currently!enrolled!in!any!other!studies?!! ! ! Yes!/!No!
19. !Are!you!a!smoker?! ! ! ! ! ! ! Yes!/!No!
20. !If!you!are!female,!to!your!knowledge,!are!you!pregnant?! ! Yes!/!No!













Participant’s!name!&!signature:!! ! ! ! _____Date:!!! ! !!





 - 1 - v1.5 131104/Ingrid Delin 
CREATININE IN URINE, by hand 96 wells 
 




NOTE! The solutions used are toxic. Consider the safety notes, and always protect 
yourself by wearing lab coat and gloves! Wear goggles when preparing reagent A. 
Read the risk assessment available in the binder in EIA lab before you start the lab work. 
 
1. Thaw the urine samples. Max 22 per 96 well plate 
Thaw at RT if you are going to use the samples within some hours. Very diluted samples 
will take longer time to thaw than the concentrated ones. 
Thaw o.n. at +4C if the samples are going to be used the next day. 
 
2. Fill in a protocol 
Note sample nr and comments for very weak or strong colour.  
 
3. Solutions: Reagents A, B and C. Standards and acetic acid. 
Prepare as below. Aq dest is deionised water from the light green tap labelled avj. 
Reagent A   store at +4C   stable for 3 months 
400 ml aq dest in a 500 mL beaker 
add 4,4 g NaOH wear goggles!    VWR 1.06469 (plätchen #6498) 
mix to dissolve 
add 9,5 g trisodium phosphate (Na3PO4
.12H20)  VWR 6578 
mix to dissolve 
add 9,5 g sodium tetra borate (Na2B4O7
.10H20) toxic! Sigma B9876-500g 
mix to dissolve 
Check that pH is >10. Adjust with 1M NaOH drop by drop if necessary. 
Add aq dest up to 500 ml. Mix well. 
 
Reagent B   store at RT   stable for 6 months 
10 g SDS (sodium dodecyl sulfate) pellets, Serva 20765 Fischer 166-207652 
Dissolve in aq dest and add aq dest up to 250 ml. 
 
Reagent C   stored in original bottle at RT in cupboard for solvents 
Picric acid saturated solution 1,3%    Sigma P6744 
Note! Picric acid is toxic. 
 
Creatinine standard set store at +4C   Sigma C3613-1 set 
0.01 mg/mL; 0.03 mg/ml; 0.1 mg/ml 
 
30% (V/V) Acetic acid store at RT    Stable for 3 months 





1. Working reagent 1 
At  analysis, freshly mix equal volumes of the reagents A, B and C.  2 
Store in a dark bottle at RT for max one week. Label with date and signature 3 
15 mL is required for each 96-well plate. 4 
 5 
Reagent A + B + C (mL) total volume (mL) nr of plates 
2 + 2 + 2 6 < ½ 
6 + 6 + 6 18 1 
10 + 10 + 10 30 2 
15 + 15 + 15 45 3 
 6 
2. Dilute the samples 7 
Turn the samples upside down a couple of times. 8 
Dilute the samples in the same way with aq dest in Ellerman tubes and mix well (vortex). 
 
Serial dilution Sample uL aq dest (ul) final dilution 
1:3 100 200 1:3, save  
1:5 from 1:3 100 400 1:15, to plate 
1:2 from 1:15 100 100 1:30, to plate 
1:2 from 1:30 60 60 1:60, use if necessary 
 9 
3. Add the blank, standards and samples to a 96 well plate, suggested 10 
template 11 
Add 40 uL of each blank/standard/sample dilution in duplicates. The blank is aq dest. 12 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
BLAN
K 1 2 3 4 5 6 7 8 9 10 11 
B 
BLAN
K 1 2 3 4 5 6 7 8 9 10 11 
C 
STD 
1 1 2 3 4 5 6 7 8 9 10 11 
D 
STD 
1 1 2 3 4 5 6 7 8 9 10 11 
E 
STD 
3 12 13 14 15 16 17 18 19 20 21 22 
F 
STD 
3 12 13 14 15 16 17 18 19 20 21 22 
G 
STD 
10 12 13 14 15 16 17 18 19 20 21 22 
H 
STD 
10 12 13 14 15 16 17 18 19 20 21 22 
 
For the samples: Add from dilution 15 and 30 for all samples in the first run.  13 
248$
$
1. Add 150 uL of working reagent to all wells 1 
Use a 2.5 mL Combitip. Setting is ‘3’. 2 
 3 
2. Incubate for exactly 30 minutes 4 
Try to keep this incubation time as consistent as possible. 5 
Incubate on the Orbital shaker, speed 150.  6 
Use a post-it note with an empty 96-well plate on top as lid. 7 
The colour will turn to more yellow by time. Dark yellow= high creatinine value. 8 
 9 
3. Start the plate reader before the 30 minutes are gone! 10 
 11 
4. Read the plate at 490 nm = BEFORE. 12 
Print and save your result. The standard curve should be linear. The duplicates should 13 
have low standard deviation values (<10%) 14 
 15 
5. Rerun samples where both dilutions failed or if the CV is not acceptable. 16 
Use the saved dilution 3 if results are too low. 17 
Dilute the 1:30 sample further to 1:60 and run if the first results are too high. 18 
 19 
6. Add Acid reagent (30% V/V Acetic Acid), work in the ventilated hood. 20 
Add 5 uL of Acid reagent to all wells. Use a 0.5 mL Combitip. Setting is ‘0,5’. 21 
 22 
7. Incubate for at least 5 minutes. 23 
Incubate on the Orbital shaker, speed 150. Use a post-it note with an empty 96-well 24 
plate on top as lid. The colour will turn back to the original yellow if the assay works 25 
OK. 26 
 27 
8. Read the plate again at 490 nm = AFTER 28 
Print and save your result. All the wells should be de-stained and no proper standard 29 
curve visible. Abs values should all be close to zero. 30 
Repeat the assay if all dilutions for the same sample fails to de-stain. In very rare 31 
cases this is due to renal disease. 32 
 33 
9. Transfer the stock urine samples back to minus 20 if not already done. 34 
 35 
10. Calculations 36 
If possible, add the proper formulas into the plate reader so the program makes all the 37 
necessary calculations for you. 38 
Bring the Excel or text file generated to your computer for further calculations. 39 
 40 
Use the BEFORE values and the conversion factor below to express data as mmol/L. 41 
 42 
Sometimes, creatinine values are expressed as mg/dL. This goes for the standards 43 
used in the method. 44 
A factor of 0,088 is used to transform data to mmol/L 45 
 46 





As long as the Abs AFTER values are close to zero, there is no need to use them in 2 
the calculations. The BEFORE results should be enough for further analysis. 3 
 4 
If you wish to stick to the original protocol, the AFTER values should be subtracted 5 
from the BEFORE values before the calculations are done. 6 
 7 
1. Expected creatinine values in urine are 1-25 mmol/L 8 
In our experience, obtained LTE4 and 9α11β PGF2 values in urine are not reliable 9 
when the creatinine values are very low; < 1 mmol/L 10 
 11 
2. QC 12 
Check that the creatinine values obtained are high when sample colour is dark and 13 
low when sample colour is light. 14 
 15 
3. Plastic ware, equipment and chemicals used 16 
 17 
1 96 well plate NUNC maxisorp 439454 VWR 
1 Combitips Eppendorf 2.5 mL 613-3521 VWR 
1 Combitips Eppendorf 0.5 mL 0030 
069.226 
VWR 
 Ellerman tubes  525-3110 VWR 
 Automatic pipettes  0,5-20; 20-200; 200-1000 uL 
 Eppendorf Multipette Plus 613-3669 VWR 
 Vortex   
 Plate shaker   
 Plate reader for 96 well plates Possibility to read at 490 nm 
     
 aq dest   deionised water 
 NaOH, pellets  6498 VWR 
 trisodium phosphate (Na3PO4.12H20) 6578 VWR 
 sodium tetra borate (Na2B4O7.10H20) B9876-500g Sigma 
 SDS, pellets preferred! Serva 20765 166-207652 Fischer Scientific 
 Picric acid  P6744 Sigma 
 Creatinine standard set C3613-1set Sigma 
 Acetic acid Glacial acetic acid   
 18 
 
 19 
